Loading...
Loading...
Virax Biolabs Group Ltd
Virax Biolabs Group Ltd. Spoken Alpha tracks VRAX's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks VRAX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for VRAX.
curl https://api.spokenalpha.com/v1/companies/VRAX| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.94 | $3.04 | +29.6% | +0.1% | +1.3% |
| Q4 FY2026 | $4.23 | $3.11 | +35.9% | -4.6% | -6.5% |
| Q3 FY2026 | $4.08 | $3.17 | +28.7% | -0.2% | -2.3% |
| Q2 FY2026 | $4.52 | $3.19 | +41.6% | -5.6% | -7.1% |
| Q1 FY2025 | $4.10 | $3.18 | +29.0% | -6.7% | -5.6% |
| Q4 FY2025 | $4.48 | $3.22 | +39.1% | -2.2% | -0.1% |
| Q3 FY2025 | $4.35 | $3.08 | +41.1% | -3.0% | -1.2% |
| Q2 FY2025 | $4.19 | $3.22 | +30.1% | +1.7% | +2.9% |
| Q1 FY2024 | $3.89 | $3.08 | +26.4% | -5.3% | -4.0% |
| Q4 FY2024 | $4.48 | $3.25 | +37.7% | +4.2% | +3.3% |